Puma Biotechnology Stock Today
| PBYI Stock | USD 3.04 0.03 0.98% |
Performance2 of 100
| Odds Of DistressLess than 5
|
Puma Biotechnology is trading at 3.04 as of the 30th of January 2025. This is a 0.98 percent decrease since the beginning of the trading day. The stock's open price was 3.07. Puma Biotechnology has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of April 2012 | Category Healthcare | Classification Health Care |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. The company has 49.09 M outstanding shares of which 3.07 M shares are at this time shorted by private and institutional investors with about 3.82 trading days to cover. More on Puma Biotechnology
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Puma Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Alan Auerbach | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPuma Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Puma Biotechnology's financial leverage. It provides some insight into what part of Puma Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Puma Biotechnology (PBYI) is traded on NASDAQ Exchange in USA. It is located in 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 and employs 185 people. Puma Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 150.7 M. Puma Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.09 M outstanding shares of which 3.07 M shares are at this time shorted by private and institutional investors with about 3.82 trading days to cover.
Puma Biotechnology currently holds about 77.96 M in cash with 27.01 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Puma Biotechnology Probability Of Bankruptcy
Ownership AllocationPuma Biotechnology owns a total of 49.09 Million outstanding shares. Over half of Puma Biotechnology's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Puma Ownership Details
Puma Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Globeflex Capital, L.p. | 2024-09-30 | 452.6 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 368.5 K | |
| Northern Trust Corp | 2024-09-30 | 317.7 K | |
| Winton Capital Group Ltd | 2024-09-30 | 309 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 305.7 K | |
| Sei Investments Co | 2024-09-30 | 288.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 281.4 K | |
| Bank Of New York Mellon Corp | 2024-09-30 | 277.7 K | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 250 K | |
| Blackrock Inc | 2024-09-30 | 3.8 M | |
| Vanguard Group Inc | 2024-09-30 | 3.6 M |
Puma Biotechnology Historical Income Statement
Puma Stock Against Markets
Puma Biotechnology Corporate Management
| Jeffrey Ludwig | Chief Officer | Profile | |
| Alvin Pharmd | Chief Officer | Profile | |
| FRAPS BSc | Pharmacovigilance, Affairs | Profile | |
| Bo Chao | Senior Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share | Quarterly Revenue Growth 0.435 | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.